Our data suggest that the presence of in situ IgG responses is associated with more aggressive pathologic features, such as HER2 overexpression and later stage of BC, as well as lower mean counts of tumor infiltrating CD8+ T cells, however the causal relationship between the IgG responses and these features remains unclear. Here, ERBB2 is linked to breast cancer.